×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BTAI – bioxcel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BTAI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
07:00 am
btai
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Medium
Report
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
4/9
07:53 pm
btai
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Medium
Report
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
4/8
07:00 am
btai
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Medium
Report
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
4/5
01:06 am
btai
BioXcel Therapeutics (BTAI) was downgraded by Wall Street Zen from "h
Medium
Report
BioXcel Therapeutics (BTAI) was downgraded by Wall Street Zen from "h
4/2
08:01 am
btai
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
4/1
07:00 am
btai
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
High
Report
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
4/1
05:53 am
btai
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D [Yahoo! Finance]
High
Report
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D [Yahoo! Finance]
3/29
12:16 pm
btai
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks [Yahoo! Finance]
Medium
Report
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
07:00 am
btai
bioxcel therapeutics, inc.
MISS
Report
-14.5%
bioxcel therapeutics, inc.
8/12/2025
07:55 am
btai
bioxcel therapeutics, inc.
MISS
Report
-17.1%
bioxcel therapeutics, inc.
5/12/2025
07:00 am
btai
bioxcel therapeutics, inc.
BEAT
Report
-4.5%
bioxcel therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/21
09:07 am
btai
Form 8-K BioXcel Therapeutics, For: Apr 15
Medium
Report
Form 8-K BioXcel Therapeutics, For: Apr 15
4/17
05:01 pm
btai
Form 8-K BioXcel Therapeutics, For: Apr 15
Low
Report
Form 8-K BioXcel Therapeutics, For: Apr 15
4/1
06:58 am
btai
Form 8-K BioXcel Therapeutics, For: Apr 01
High
Report
Form 8-K BioXcel Therapeutics, For: Apr 01
3/30
12:10 pm
btai
Form SCHEDULE 13G/A BioXcel Therapeutics, Filed by: Qatar Investment Authority
Low
Report
Form SCHEDULE 13G/A BioXcel Therapeutics, Filed by: Qatar Investment Authority
3/27
05:10 pm
btai
Form S-8 BioXcel Therapeutics,
Medium
Report
Form S-8 BioXcel Therapeutics,
3/27
05:02 pm
btai
Form 10-K BioXcel Therapeutics, For: Dec 31
Medium
Report
Form 10-K BioXcel Therapeutics, For: Dec 31
3/27
07:21 am
btai
Form 8-K BioXcel Therapeutics, For: Mar 27
Medium
Report
Form 8-K BioXcel Therapeutics, For: Mar 27
3/16
08:06 pm
btai
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Mehta Vimal
High
Report
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Mehta Vimal
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/31
BioXcel Therapeutics Inc (NASDAQ: BTAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
40.3%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
TOP News Decliners
3/14
BioXcel Therapeutics Inc (NASDAQ: BTAI) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
-26.4%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: